Syros Pharmaceuticals Presents Data Demonstrating Significant …
Syros in-licensed SY-1425, which is approved in Japan as tamibarotene to treat acute promyelocytic leukemia, to develop and commercialize SY-1425 in North America and Europe …
SYROS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)
Press Releases - Syros Pharmaceuticals, Inc. (SYRS)
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer Sep 7, 2022
Re: Syros Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-239141) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the …
Syros to Present at Piper Jaffray 31st Annual Healthcare Conference
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines …
Syros Announces Proposed Concurrent Public Offerings of …
Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes.
Syros Pharmaceuticals, Inc.
We would like to show you a description here but the site won’t allow us.